Institutional Ownership
Teva Pharmaceutical Inds Ltd
CUSIP 881624209SPONSORED ADSTEVAQ1 2026
Latest EPS (Diluted)
$-0.49
Q2 2026 · Jun 30, 2026
Latest Revenue
$4.14B
Reported quarter
Latest Net Income
-$576.00M
Reported quarter
Quarters on Record
12
From SEC XBRL filings
Quarterly Earnings
EPS, revenue & net income · SEC XBRL (10-Q / 10-K)
| Period | Quarter | EPS (Basic) | EPS (Diluted) | Revenue | Net Income | Form |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | Q2 2026 | $-0.49 | $-0.49 | $4.14B | -$576.00M | 10-Q |
| Mar 31, 2026 | Q1 2026 | $0.32 | $0.31 | $3.98B | $369.00M | 10-Q |
| Dec 31, 2025 | Q4 2025 | — | — | $1.50B | — | 10-K |
| Sep 30, 2025 | Q3 2025 | $0.38 | $0.37 | $4.48B | $433.00M | 10-Q |
| Jun 30, 2025 | Q2 2025 | $0.25 | $0.24 | $4.18B | $282.00M | 10-Q |
| Mar 31, 2025 | Q1 2025 | $0.19 | $0.18 | $3.89B | $214.00M | 10-Q |
| Sep 30, 2024 | Q3 2024 | $-0.39 | $-0.39 | $4.33B | -$437.00M | 10-Q |
| Jun 30, 2024 | Q2 2024 | $-0.75 | $-0.75 | $4.16B | -$846.00M | 10-Q |
| Mar 31, 2024 | Q1 2024 | $-0.12 | $-0.12 | $3.82B | -$139.00M | 10-Q |
| Sep 30, 2023 | Q3 2023 | $0.06 | $0.06 | $3.85B | $69.00M | 10-Q |
| Jun 30, 2023 | Q2 2023 | $-0.78 | $-0.78 | $3.88B | -$872.00M | 10-Q |
| Mar 31, 2023 | Q1 2023 | $-0.20 | $-0.20 | $3.66B | -$220.00M | 10-Q |